

Roman Rouzier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6304008/publications.pdf>

Version: 2024-02-01

300
papers

17,447
citations

18482

62
h-index

18130

120
g-index

360
all docs

360
docs citations

360
times ranked

16214
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5678-5685.	7.0	1,618
2	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4236-4244.	1.6	621
3	Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7265-7277.	1.6	531
4	Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). <i>Lancet Oncology</i> , The, 2011, 12, 469-476.	10.7	457
5	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1508-1516.	1.5	401
6	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. <i>Journal of Clinical Oncology</i> , 2004, 22, 3302-3308.	1.6	389
7	Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8315-8320.	7.1	368
8	Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 9304-9311.	1.6	366
9	Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. <i>Fertility and Sterility</i> , 2009, 92, 1825-1833.	1.0	354
10	Hypertrophy of labia minora: Experience with 163 reductions. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 182, 35-40.	1.3	280
11	Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes. <i>Journal of Clinical Oncology</i> , 2002, 20, 1304-1310.	1.6	272
12	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 682-691.	4.1	267
13	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8331-8339.	1.6	266
14	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4952-4960.	1.6	258
15	Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. <i>Journal of the American College of Surgeons</i> , 2003, 197, 198-205.	0.5	245
16	Breast cancer in pregnancy: Recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , 2010, 46, 3158-3168.	2.8	238
17	Quality of life after laparoscopic colorectal resection for endometriosis. <i>Human Reproduction</i> , 2006, 21, 1243-1247.	0.9	237
18	Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: A Prospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2800-2808.	1.6	231

#	ARTICLE	IF	CITATIONS
19	Randomized Trial of Laparoscopically Assisted Versus Open Colorectal Resection for Endometriosis. <i>Annals of Surgery</i> , 2010, 251, 1018-1023.	4.2	218
20	Adnexal Masses: Development and Preliminary Validation of an MR Imaging Scoring System. <i>Radiology</i> , 2013, 267, 432-443.	7.3	176
21	Characterization of Complex Adnexal Masses: Value of Adding Perfusion- and Diffusion-weighted MR Imaging to Conventional MR Imaging. <i>Radiology</i> , 2011, 258, 793-803.	7.3	167
22	Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 343-352.	2.5	163
23	Identification and Functional Analysis of a New WNT4 Gene Mutation among 28 Adolescent Girls with Primary Amenorrhea and Müllerian Duct Abnormalities: A French Collaborative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 895-900.	3.6	162
24	Laparoscopic radical hysterectomy for invasive cervical cancer: 8-year experience of a pilot study. <i>Gynecologic Oncology</i> , 2003, 91, 534-539.	1.4	154
25	Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2014, 101, 785-794.e3.	1.0	151
26	Dynamic contrast-enhanced magnetic resonance imaging: A useful tool for characterizing ovarian epithelial tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 111-120.	3.4	150
27	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 832-837.	2.5	149
28	Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. <i>Cancer</i> , 2004, 100, 1365-1373.	4.1	143
29	How to differentiate benign from malignant myometrial tumours using MR imaging. <i>European Radiology</i> , 2013, 23, 2306-2314.	4.5	143
30	Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery. <i>Journal of Clinical Oncology</i> , 2001, 19, 3828-3835.	1.6	141
31	Taxanes for breast cancer during pregnancy: a systematic review. <i>Annals of Oncology</i> , 2010, 21, 425-426.	1.2	141
32	Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. <i>Journal of the American College of Surgeons</i> , 2003, 196, 442-450.	0.5	139
33	Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2032-2037.	1.6	132
34	Laparoscopic segmental colorectal resection for endometriosis: limits and complications. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007, 21, 1572-1577.	2.4	129
35	Anaphylactic response to blue dye during sentinel lymph node biopsy. <i>Surgical Oncology</i> , 2011, 20, e55-e59.	1.6	128
36	Sentinel node biopsy for the management of early stage endometrial cancer: Long-term results of the SENTI-ENDO study. <i>Gynecologic Oncology</i> , 2015, 136, 54-59.	1.4	128

#	ARTICLE	IF	CITATIONS
37	External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score. <i>Gynecologic Oncology</i> , 2008, 110, 354-359.	1.4	126
38	Surgical routes and complications of hysterectomy for benign disorders: a prospective observational study in French university hospitals. <i>Human Reproduction</i> , 2007, 22, 260-265.	0.9	119
39	The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma. <i>PLoS ONE</i> , 2011, 6, e20297.	2.5	105
40	Local relapse in patients treated for squamous cell vulvar carcinoma Incidence and prognostic value. <i>Obstetrics and Gynecology</i> , 2002, 100, 1159-1167.	2.4	101
41	Urinary Complications After Surgery for Posterior Deep Infiltrating Endometriosis are Related to the Extent of Dissection and to Uterosacral Ligaments Resection. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 235-240.	0.6	99
42	Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7098-7104.	1.6	98
43	Outcome of laparoscopic colorectal resection for endometriosis. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 308-313.	2.0	91
44	Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers. <i>Human Reproduction</i> , 2009, 24, 3082-3089.	0.9	88
45	Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 621-637.	2.5	87
46	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. <i>European Journal of Cancer</i> , 2017, 70, 133-142.	2.8	86
47	Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. <i>European Radiology</i> , 2012, 22, 738-745.	4.5	82
48	Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4287-4292.	1.6	81
49	Use of the SF-36 questionnaire to predict quality-of-life improvement after laparoscopic colorectal resection for endometriosis. <i>Human Reproduction</i> , 2008, 23, 846-851.	0.9	80
50	Perineoplasty for the treatment of introital stenosis related to vulvar lichen sclerosus. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 49-52.	1.3	79
51	Breast cancer stroma frequently recruits fetal derived cells during pregnancy. <i>Breast Cancer Research</i> , 2008, 10, R14.	5.0	78
52	Results of conservative management of epithelial malignant and borderline ovarian tumours. <i>Human Reproduction Update</i> , 2003, 9, 185-192.	10.8	77
53	Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 178.e1-178.e10.	1.3	75
54	Fertility after colorectal resection for endometriosis: results of a prospective study comparing laparoscopy with open surgery. <i>Fertility and Sterility</i> , 2011, 95, 1903-1908.	1.0	75

#	ARTICLE	IF	CITATIONS
55	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, 2233-2240.	1.2	75
56	Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo. <i>Cell Cycle</i> , 2005, 4, 1149-1152.	2.6	74
57	Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 711-718.	7.0	72
58	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	6.3	71
59	Laparoscopic total pelvic exenteration for cervical cancer relapse. <i>Gynecologic Oncology</i> , 2003, 91, 616-618.	1.4	70
60	Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. <i>British Journal of Cancer</i> , 2013, 108, 285-291.	6.4	70
61	Immediate Reconstruction After Neoadjuvant Chemotherapy: Effect on Adjuvant Treatment Starting and Survival. <i>Annals of Surgical Oncology</i> , 2005, 12, 161-166.	1.5	69
62	Prognostic Significance of Epithelial Disorders Adjacent to Invasive Vulvar Carcinomas. <i>Gynecologic Oncology</i> , 2001, 81, 414-419.	1.4	65
63	Expression of sigma 1 receptor in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 205-214.	2.5	65
64	Use of the Sentinel Node Procedure to Stage Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1523-1529.	1.5	65
65	Nonmasslike Enhancement at Breast MR Imaging: The Added Value of Mammography and US for Lesion Categorization. <i>Radiology</i> , 2011, 261, 69-79.	7.3	63
66	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. <i>Cancer</i> , 2004, 101, 918-925.	4.1	62
67	Pregnancy-associated breast cancers: Do they differ from other breast cancers in young women?. <i>Breast</i> , 2012, 21, 550-555.	2.2	59
68	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor- and human epidermal growth factor receptor 2-negative early-stage breast cancer. <i>European Journal of Cancer</i> , 2016, 66, 104-113.	2.8	59
69	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. <i>Modern Pathology</i> , 2018, 31, 68-82.	5.5	58
70	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. <i>Cancer</i> , 2006, 107, 1459-1466.	4.1	55
71	The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2010, 117, 1451-1458.	2.3	55
72	CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2014, 135, 542-546.	1.4	55

#	ARTICLE	IF	CITATIONS
73	A single-institution study of 117 pregnancy-associated breast cancers (PABC): Presentation, imaging, clinicopathological data and outcome. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 435-441.	3.2	54
74	Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 244.e1-244.e7.	1.3	53
75	Tumoral heterogeneity of breast cancer. <i>Annales De Biologie Clinique</i> , 2016, 74, 653-660.	0.1	53
76	Multiple synchronous (multifocal and multicentric) breast cancer: Clinical implications. <i>Surgical Oncology</i> , 2010, 19, e115-e123.	1.6	52
77	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 2591-2601.	7.0	52
78	Increased fetal cell microchimerism in high grade breast carcinomas occurring during pregnancy. <i>International Journal of Cancer</i> , 2009, 124, 1054-1059.	5.1	50
79	Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. <i>Fertility and Sterility</i> , 2012, 98, 1229-1235.	1.0	50
80	A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 197.e1-197.e8.	1.3	49
81	Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 537-543.	2.5	48
82	Sentinel lymph node biopsy in gynaecological cancers: The importance of micrometastases in cervical cancer. <i>Surgical Oncology</i> , 2008, 17, 227-235.	1.6	47
83	Germline <i>RAD51C</i> mutations in ovarian cancer susceptibility. <i>Clinical Genetics</i> , 2013, 83, 332-336.	2.0	46
84	Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2015, 136, 112-120.	1.4	45
85	Psychometric properties of the French Female Sexual Function Index (FSFI). <i>Quality of Life Research</i> , 2014, 23, 2079-2087.	3.1	44
86	Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. <i>British Journal of Cancer</i> , 2021, 124, 777-785.	6.4	44
87	Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. <i>PLoS ONE</i> , 2015, 10, e0132853.	2.5	44
88	Value of ultrasonography and magnetic resonance imaging for the characterization of uterine mesenchymal tumors. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 261-268.	2.8	43
89	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015, 20, 873-879.	3.7	43
90	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1689-1702.	3.3	43

#	ARTICLE	IF	CITATIONS
91	Predictive factors for complete excision and underestimation of one-pass en bloc excision of non-palpable breast lesions with the Intact [®] breast lesion excision system. <i>European Journal of Radiology</i> , 2012, 81, 719-724.	2.6	42
92	Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey. <i>Annals of Surgical Oncology</i> , 2015, 22, 3504-3511.	1.5	42
93	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 76.	5.0	41
94	Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 129, 292-297.	1.4	40
95	Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. <i>Breast Cancer Research</i> , 2014, 16, R46.	5.0	40
96	Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. <i>British Journal of Cancer</i> , 2016, 114, 44-52.	6.4	40
97	Specimen radiography as predictor of resection margin status in non-palpable breast lesions. <i>Clinical Radiology</i> , 2006, 61, 789-796.	1.1	39
98	Expression of MMP-2, α^7 , α^9 , MT1-MMP and TIMP-1 and α^2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. <i>Oncology Reports</i> , 2012, 27, 1049-1057.	2.6	39
99	A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. <i>Endocrine-Related Cancer</i> , 2005, 12, 1059-1069.	3.1	38
100	Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?. <i>BMC Cancer</i> , 2010, 10, 465.	2.6	38
101	Preoperative Evaluation of Posterior Deep-Infiltrating Endometriosis Demonstrates a Relationship with Urinary Dysfunction and Parametrial Involvement. <i>Journal of Minimally Invasive Gynecology</i> , 2011, 18, 36-42.	0.6	38
102	Comparison of Diagnostic Accuracy of Frozen Section with Imprint Cytology for Intraoperative Examination of Sentinel Lymph Node in Early-Stage Endometrial Cancer: Results of Senti-Endo Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 3515-3521.	1.5	38
103	The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. <i>International Journal of Clinical Practice</i> , 2008, 62, 1730-1735.	1.7	37
104	α 1 and α 5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment. <i>European Journal of Immunology</i> , 2012, 42, 1599-1608.	2.9	37
105	Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. <i>ESMO Open</i> , 2018, 3, e000339.	4.5	37
106	Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. <i>EBioMedicine</i> , 2019, 43, 253-260.	6.1	37
107	Ultrastaging of lymph node in uterine cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 5.	8.6	36
108	Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. <i>International Journal of Hyperthermia</i> , 2004, 20, 405-419.	2.5	35

#	ARTICLE	IF	CITATIONS
109	Limits of lymphoscintigraphy for sentinel node biopsy in women with endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 112, 348-352.	1.4	35
110	Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. <i>BMJ Open</i> , 2018, 8, e020276.	1.9	35
111	The role of neoadjuvant chemotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 555-566.	2.4	34
112	Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantâ„¢ Microarray Based Assay. <i>PLoS ONE</i> , 2016, 11, e0146474.	2.5	34
113	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	1.8	34
114	The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma. <i>Cancer</i> , 2004, 101, 1482-1489.	4.1	33
115	Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 619-627.	2.5	33
116	Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 213-215.	6.3	33
117	High rate of <i>PIK3CA</i> mutations but no <i>TP53</i> mutations in low-grade adenosquamous carcinoma of the breast. <i>Histopathology</i> , 2018, 73, 273-283.	2.9	33
118	Chemotherapy for breast cancer during pregnancy: is epirubicin safe?. <i>Annals of Oncology</i> , 2008, 19, 1814-1815.	1.2	32
119	Prospective Multicenter Comparison of Models to Predict Four or More Involved Axillary Lymph Nodes in Patients With Breast Cancer With One to Three Metastatic Sentinel Lymph Nodes. <i>Journal of Clinical Oncology</i> , 2009, 27, 5707-5712.	1.6	32
120	Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. <i>BMC Cancer</i> , 2009, 9, 171.	2.6	31
121	Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2009, 116, 1062-1068.	2.3	31
122	Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy. <i>Gynecologic Oncology</i> , 2004, 95, 402-404.	1.4	30
123	A double blind randomized trial of wound infiltration with ropivacaine after breast cancer surgery with axillary nodes dissection. <i>BMC Anesthesiology</i> , 2011, 11, 23.	1.8	30
124	A suggested modification to FIGO stage I endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 192-196.	1.4	30
125	Staging for endometrial cancer: The controversy around lymphadenectomy â€œ Can this be resolved?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 845-857.	2.8	30
126	Breast cancer in young women: Pathologic features and molecular phenotype. <i>Breast</i> , 2016, 29, 109-116.	2.2	30

#	ARTICLE	IF	CITATIONS
127	Coverage and Compliance of Human Papillomavirus Vaccines in Paris: Demonstration of Low Compliance With Non-School-Based Approaches. <i>Journal of Adolescent Health</i> , 2010, 47, 237-241.	2.5	29
128	Development and Validation of a Nomogram for Predicting Outcome of Patients With Vulvar Cancer. <i>Obstetrics and Gynecology</i> , 2006, 107, 672-677.	2.4	28
129	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1003-1009.	6.4	28
130	Surgery for Vulvar Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 869-878.	1.1	27
131	The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy. <i>Cancer</i> , 2005, 104, 229-235.	4.1	27
132	Contribution of the sentinel node procedure to tailoring the radicality of hysterectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2007, 106, 251-256.	1.4	27
133	Laparoscopic versus laparotomic radical en bloc hysterectomy and colorectal resection for endometriosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 3060-3067.	2.4	27
134	Diagnostic Performance of Ultrasound-Guided Fine-Needle Aspiration of Nonpalpable Breast Lesions in a Multidisciplinary Setting. <i>American Journal of Clinical Pathology</i> , 2017, 147, 571-579.	0.7	27
135	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0144359.	2.5	27
136	Tattooing Breast Cancers Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 2233-2238.	1.5	26
137	The Usefulness of a Preoperative Compact Imager, a Hand-Held ^{131}I -Camera for Breast Cancer Sentinel Node Biopsy: Final Results of a Prospective Double-Blind, Clinical Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1346-1353.	5.0	26
138	Trends in Treatment and Survival of Late-Stage Squamous Cell Vulvar Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 854-859.	2.5	26
139	Sexual and functional results after creation of a neovagina in women with Mayer-Rokitansky-Kuster-Hauser syndrome: a comparison of nonsurgical and surgical procedures. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 169, 317-320.	1.1	26
140	Survival impact and predictive factors of axillary recurrence after sentinel biopsy. <i>European Journal of Cancer</i> , 2016, 58, 73-82.	2.8	26
141	Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases. <i>Breast</i> , 2016, 30, 222-227.	2.2	26
142	Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. <i>Annals of Oncology</i> , 2011, 22, 1582-1587.	1.2	25
143	Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 30-36.	6.4	25
144	Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 1980-1986.	1.5	25

#	ARTICLE	IF	CITATIONS
145	Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. <i>International Journal of Oncology</i> , 2008, 33, 1239-46.	3.3	25
146	Radiofrequency Thermal Ablation of Breast Cancer Local Recurrence: A Phase II Clinical Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 3222-3226.	1.5	24
147	Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 148, 186-190.	1.1	24
148	The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 500.e1-500.e11.	1.3	23
149	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. <i>British Journal of Cancer</i> , 2016, 115, 1024-1031.	6.4	23
150	Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 61.	3.0	23
151	Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer. <i>British Journal of Cancer</i> , 2013, 108, 1267-1272.	6.4	22
152	Predictive and Prognostic Value of the TauProtein in Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 5179-84.	1.1	22
153	Pathologic Response Rate After Concomitant Neo-Adjuvant Radiotherapy and Chemotherapy for Adenocarcinoma of the Uterine Cervix: A Retrospective Multicentric Study. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 815-820.	2.5	21
154	Surgical resection of liver metastases from breast cancer. <i>Surgical Oncology</i> , 2010, 19, e79-e84.	1.6	21
155	Four-year functional results of the suburethral sling procedure for stress urinary incontinence: a French prospective randomized multicentre study comparing the retropubic and transobturator routes. <i>World Journal of Urology</i> , 2012, 30, 117-122.	2.2	21
156	Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 996-1002.	6.4	21
157	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial. <i>Vaccine</i> , 2018, 36, 98-106.	3.8	21
158	Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 219.	2.3	21
159	The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IB3 cervical cancer. <i>Anticancer Research</i> , 2013, 33, 1661-6.	1.1	21
160	Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, e15-e16.	1.3	20
161	Secondary Complete Cytoreduction in Recurrent Ovarian Cancer: Benefit of Optimal Patient Selection Using Scoring System. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 238-246.	2.5	20
162	Lymph node positivity in different early breast carcinoma phenotypes: a predictive model. <i>BMC Cancer</i> , 2019, 19, 45.	2.6	20

#	ARTICLE	IF	CITATIONS
163	Primary adenocarcinoma of the rectovaginal septum: a case report and literature review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001, 95, 111-113.	1.1	19
164	Development and validation of nomograms for predicting preterm delivery. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 242.e1-242.e8.	1.3	19
165	Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 2195-2200.	6.4	19
166	The patient-breast cancer care pathway: how could it be optimized?. <i>BMC Cancer</i> , 2015, 15, 394.	2.6	19
167	Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1846.	3.7	19
168	Sentinel lymph node procedure followed by laparoscopic pelvic and paraaortic lymphadenectomy in women with IB2-II cervical cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2654-2661.	1.5	18
169	Antibacterial-Coated Suture in Reducing Surgical Site Infection in Breast Surgery: A Prospective Study. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-8.	1.2	18
170	Prediction of axillary lymph node status in male breast carcinoma. <i>Annals of Oncology</i> , 2013, 24, 370-376.	1.2	18
171	Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 172, 115-119.	1.1	18
172	Determinants of geographic inequalities in HPV vaccination in the most populated region of France. <i>PLoS ONE</i> , 2017, 12, e0172906.	2.5	18
173	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification. <i>PLoS ONE</i> , 2012, 7, e47390.	2.5	18
174	Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. <i>Annals of Oncology</i> , 2006, 17, 1644-1649.	1.2	17
175	Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. <i>BMC Bioinformatics</i> , 2008, 9, 149.	2.6	17
176	Genital Prolapse Repair Using Porcine Skin Implant and Bilateral Sacrospinous Fixation: Midterm Functional Outcome and Quality-of-Life Assessment. <i>Urology</i> , 2009, 73, 245-250.	1.0	17
177	Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2-II cervical cancer. <i>British Journal of Cancer</i> , 2012, 106, 39-44.	6.4	17
178	Comparison of Morbidity and Survival Between Primary and Interval Cytoreductive Surgery in Patients After Modified Posterior Pelvic Exenteration for Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1349-1354.	2.5	17
179	Effects of pelvic organ prolapse repair on urinary symptoms: A comparative study between the laparoscopic and vaginal approach. <i>Neurourology and Urodynamics</i> , 2012, 31, 126-131.	1.5	17
180	Accuracy of diagnosis on CT scan of Surgicel® Fibrillar: results of a prospective blind reading study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 169, 397-401.	1.1	17

#	ARTICLE	IF	CITATIONS
181	Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators. <i>British Journal of Cancer</i> , 2017, 116, 1394-1401.	6.4	17
182	HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports. <i>BMC Cancer</i> , 2019, 19, 375.	2.6	17
183	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. <i>Drug Resistance Updates</i> , 2004, 7, 325-331.	14.4	16
184	Superficially Invasive Carcinoma of the Vulva: Diagnosis and Treatment. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 862-868.	1.1	16
185	Update on the role of laparoscopy in the treatment of gynaecological malignancy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 77-82.	2.0	16
186	Gene expression profiling of primary breast cancer. <i>Current Oncology Reports</i> , 2005, 7, 38-44.	4.0	16
187	Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. <i>Surgical Oncology</i> , 2010, 19, e47-e55.	1.6	16
188	Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 601-607.	2.5	16
189	From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer. <i>BMC Cancer</i> , 2015, 15, 842.	2.6	16
190	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 307-316.	2.5	16
191	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 111-122.	2.5	16
192	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. <i>PLoS ONE</i> , 2013, 8, e76496.	2.5	16
193	Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer. <i>Anticancer Research</i> , 2014, 34, 3997-4003.	1.1	16
194	Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 123, 214-220.	1.4	15
195	Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. <i>PLoS ONE</i> , 2016, 11, e0159888.	2.5	15
196	Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. <i>PLoS ONE</i> , 2017, 12, e0185753.	2.5	15
197	Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2173-2179.	1.5	14
198	Clues pointing to simple hysterectomy to treat early-stage cervical cancer. <i>Oncology Reports</i> , 2009, 22, 927-34.	2.6	14

#	ARTICLE	IF	CITATIONS
199	Eutopic endometrium and peritoneal, ovarian and colorectal endometriotic tissues express a different profile of Nectin-1, -3, -4 and nectin-like molecule 2. <i>Human Reproduction</i> , 2012, 27, 3179-3186.	0.9	14
200	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3560-3570.	6.4	14
201	Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 4865-4872.	1.1	14
202	Local Relapse in Patients Treated for Squamous Cell Vulvar Carcinoma. <i>Obstetrics and Gynecology</i> , 2002, 100, 1159-1167.	2.4	13
203	Unusual presentation of Bartholin's gland duct cysts: anterior expansions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 1150-1152.	2.3	13
204	Experience with TachoSil in obstetric and gynecologic surgery. <i>International Journal of Gynecology and Obstetrics</i> , 2011, 113, 112-115.	2.3	13
205	Interest in cavity shaving in breast conservative treatment does not depend on lumpectomy technique. <i>Breast</i> , 2011, 20, 358-364.	2.2	13
206	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. <i>Journal of Medical Economics</i> , 2012, 15, 1167-1175.	2.1	13
207	Anorectal symptoms before and after laparoscopic sacrocolpoperineopexy for pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2012, 23, 779-783.	1.4	13
208	Non-Invasive Tools for the Diagnosis of Potentially Life-Threatening Gynaecological Emergencies: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0114189.	2.5	13
209	Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. <i>British Journal of Cancer</i> , 2015, 112, 912-917.	6.4	13
210	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	13
211	Development and validation of a nomogram to predict the risk of cesarean delivery in macrosomia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 518-523.	2.8	12
212	Development of a nomogram to predict occurrence of preeclampsia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 137, 146-151.	1.1	12
213	Discordance With Local Guidelines for Adjuvant Chemotherapy in Breast Cancer: Reasons and Effect on Survival. <i>Clinical Breast Cancer</i> , 2011, 11, 46-51.	2.4	12
214	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. <i>American Journal of Pathology</i> , 2018, 188, 2378-2391.	3.8	12
215	Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. <i>Anticancer Research</i> , 2013, 33, 3015-9.	1.1	12
216	A suggested modification to FIGO stage III vulvar cancer. <i>Gynecologic Oncology</i> , 2008, 110, 83-86.	1.4	11

#	ARTICLE	IF	CITATIONS
217	Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 525-529.	2.8	11
218	Survival Impact of Lymphadenectomy Stratified by Nodal Metastatic Probability in Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2376-2382.	1.5	11
219	Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study. <i>PLoS ONE</i> , 2019, 14, e0210917.	2.5	11
220	Frozen section examination of the endocervical margin of cervical conization specimens. <i>Gynecologic Oncology</i> , 2003, 90, 305-309.	1.4	10
221	Kaposi's Sarcoma and Pregnancy: Case Report and Literature Review. <i>Dermatology</i> , 2013, 226, 311-314.	2.1	10
222	Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach. <i>PLoS ONE</i> , 2019, 14, e0208807.	2.5	10
223	Genetic markers and phosphoprotein forms of beta-catenin p ¹² -Cat552 and p ¹² -Cat675 are prognostic biomarkers of cervical cancer. <i>EBioMedicine</i> , 2020, 61, 103049.	6.1	10
224	Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. <i>Anticancer Research</i> , 2016, 36, 1865-71.	1.1	10
225	Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 325-331.	2.5	9
226	An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they?. <i>British Journal of Cancer</i> , 2013, 109, 1498-1503.	6.4	9
227	Reexcision for positive margins in breast cancer: A predictive score of residual disease. <i>Surgical Oncology</i> , 2015, 24, 129-135.	1.6	9
228	Choroidal melanoma and pregnancy. <i>Acta Ophthalmologica</i> , 2016, 94, e652-e660.	1.1	9
229	Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?. <i>Public Health Genomics</i> , 2016, 19, 144-152.	1.0	9
230	Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.. <i>Journal of Clinical Oncology</i> , 2012, 30, 568-568.	1.6	9
231	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. <i>PLoS ONE</i> , 2016, 11, e0148957.	2.5	9
232	Clinical validation of a model predicting the risk of preterm delivery. <i>PLoS ONE</i> , 2017, 12, e0171801.	2.5	9
233	Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. <i>Anticancer Research</i> , 2010, 30, 4743-7.	1.1	9
234	A nomogram to predict for malignant diagnosis of BI-RADS category 4 breast lesions. <i>Journal of Surgical Oncology</i> , 2010, 102, 220-224.	1.7	8

#	ARTICLE	IF	CITATIONS
235	Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 194, 106-110.	1.1	8
236	Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer. <i>Breast</i> , 2015, 24, 370-375.	2.2	8
237	Direct Comparison of Logistic Regression and Recursive Partitioning to Predict Lymph Node Metastasis in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1037-1043.	2.5	8
238	Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTECS study. <i>British Journal of Cancer</i> , 2017, 116, 1135-1140.	6.4	8
239	Pregnancy stimulates tumor angiogenesis in breast carcinoma. <i>Anticancer Research</i> , 2014, 34, 125-31.	1.1	8
240	Retroperitoneal Lymphangioliomyoma Mimicking Ovarian Tumor Emerging After Tamoxifen Therapy. <i>Obstetrics and Gynecology</i> , 2006, 108, 762-764.	2.4	7
241	Prognostic Value of the 2009 FIGO Staging for Endometrial Cancer: An Illustration of the E3N Cohort. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 447-451.	2.5	7
242	Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB). <i>Breast</i> , 2017, 34, 24-33.	2.2	7
243	Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 73-81.	2.5	7
244	Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma. <i>Molecular Oncology</i> , 2022, 16, 3001-3016.	4.6	7
245	Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. <i>Obstetrics and Gynecology</i> , 2011, 117, 1225-1226.	2.4	6
246	Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to Prediction in Oncogenomics. <i>Cancer Informatics</i> , 2015, 14, CIN.S21111.	1.9	6
247	Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 101871.	1.3	6
248	Benign lipoblastomalike tumor of the vulva: report of a case affecting a young patient. <i>Journal of reproductive medicine, The</i> , 2007, 52, 223-4.	0.2	6
249	The Google news effect: did the tainted milk scandal in China temporarily impact newborn feeding patterns in a maternity hospital?. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2010, 89, 823-827.	2.8	5
250	Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 919-926.	2.5	5
251	CCR 20th Anniversary Commentary: Divide and Conquer Breast Cancer Subtypes and Response to Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3575-3577.	7.0	5
252	Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study. <i>Cancers</i> , 2021, 13, 1593.	3.7	5

#	ARTICLE	IF	CITATIONS
253	Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e352-e361.	2.4	5
254	Evaluation and Selection of Quality Indicators for the Management of Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 979-986.	2.5	5
255	Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network. <i>Supportive Care in Cancer</i> , 2022, 30, 5991-5999.	2.2	5
256	Correction of uterine prolapse by the vaginal route using the uterosacral ligaments: Shirodkar procedure. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 109, 214-218.	1.1	4
257	Stage 1A squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2006, 103, 375-376.	1.4	4
258	Simultaneous early ovarian and endometrial cancer treated conservatively with spontaneous pregnancy. <i>Journal of Ovarian Research</i> , 2013, 6, 59.	3.0	4
259	Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database. <i>Bulletin Du Cancer</i> , 2015, 102, 892-897.	1.6	4
260	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	2.2	4
261	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. <i>PLoS ONE</i> , 2017, 12, e0169962.	2.5	4
262	Correlation of ultrasound, cytological, and histological features of 110 benign BI-RADS categories 4C and 5 nonpalpable breast lesions. The Institut Curie's experience. <i>Cancer Cytopathology</i> , 2021, 129, 479-488.	2.4	4
263	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. <i>PLoS ONE</i> , 2016, 11, e0156096.	2.5	4
264	Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study). <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002888.	2.5	4
265	Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 5111-6.	1.1	4
266	Transvaginal Hydrolaparoscopy: Practices in French Teaching Hospitals. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 273-276.	0.6	3
267	Semi-supervised model applied to the prediction of the response to preoperative chemotherapy for breast cancer. <i>Soft Computing</i> , 2011, 15, 1137-1144.	3.6	3
268	Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 601-606.	2.5	3
269	Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. <i>PLoS ONE</i> , 2018, 13, e0202385.	2.5	3
270	Threatened preterm birth: Validation of a nomogram to predict the individual risk of very preterm delivery in a secondary care center. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2019, 48, 501-507.	1.3	3

#	ARTICLE	IF	CITATIONS
271	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. <i>Gynecologic Oncology</i> , 2021, 163, 64-71.	1.4	3
272	Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. <i>Vaccine</i> , 2021, 39, 5129-5137.	3.8	3
273	Downsizing Multigenic Predictors of the Response to Preoperative Chemotherapy in Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2008, , 157-164.	1.3	3
274	Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management. <i>Anticancer Research</i> , 2012, 32, 3403-9.	1.1	3
275	Immunocytochemical detection of bone marrow micrometastases in colorectal carcinoma patients, using a monoclonal antibody to villin. <i>Cytometry</i> , 2001, 46, 281-289.	1.8	2
276	The subtleties of intestinal metaplasia. <i>Gut</i> , 2001, 49, 8-8.	12.1	2
277	Can the centrosome be a marker for DNA ploidy in breast cancer?. <i>Journal of Cytology</i> , 2012, 29, 111.	0.6	2
278	New Multi-Objective Algorithms for Neural Network Training Applied to Genomic Classification Data. <i>Studies in Computational Intelligence</i> , 2009, , 63-82.	0.9	1
279	RE: External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score. <i>Gynecologic Oncology</i> , 2009, 112, 286.	1.4	1
280	Non-parametric kernel density estimation for the prediction of neoadjuvant chemotherapy outcomes. , 2010, 2010, 1775-8.		1
281	Laparoscopic pelvic lymph node dissection. <i>Journal of Visceral Surgery</i> , 2011, 148, e111-e116.	0.8	1
282	Anti-cancer agents for breast cancer treatment during pregnancy. <i>Journal of Surgical Oncology</i> , 2011, 104, 560-560.	1.7	1
283	Skin Lesions after Prophylactic Mastectomy and Immediate Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2013, 1, e82.	0.6	1
284	Genomic profile of breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 393-394.	1.4	1
285	Denaturing fixatives are compatible with the NanoString nCounter [®] platform and the Prosigna [®] assay. <i>New Biotechnology</i> , 2017, 36, 37-41.	4.4	1
286	Faisabilité et tolérance de Sienna+ [®] pour la détection du ganglion sentinelle: Étude pilote unicentrique sur 30 cas consécutifs. <i>Cancer Radiothérapie: Journal De La Societe Francaise De Radiothérapie Oncologique</i> , 2017, 21, 305-306.	1.4	1
287	Associated Lichen Sclerosis Increases the Risk of Lymph Node Metastases of Vulvar Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 250.	2.4	1
288	Bayesian Classifiers for Predicting the Outcome of Breast Cancer Preoperative Chemotherapy. <i>Lecture Notes in Computer Science</i> , 2008, , 263-266.	1.3	1

#	ARTICLE	IF	CITATIONS
289	Value of Diaphragmatic Surgery During Interval Debulking Surgery. <i>Anticancer Research</i> , 2018, 38, 411-416.	1.1	1
290	Impact of catch-up human papillomavirus vaccination on cervical conization rate in a real-life population in France. <i>PLoS ONE</i> , 2022, 17, e0264821.	2.5	1
291	The benefit of combined maternal administration of magnesium sulfate and aminophylline. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 592-593.	1.3	0
292	Laparoscopic lumbo-aortic lymph node dissection. <i>Journal of Visceral Surgery</i> , 2011, 148, e273-e278.	0.8	0
293	Rectovaginal Endometriosis. <i>Annals of Surgery</i> , 2011, 254, 540-541.	4.2	0
294	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, e17.	1.3	0
295	Response to the letter "More data along with further definitions are required" by Sahin et al.. <i>Breast</i> , 2016, 30, 230-233.	2.2	0
296	Colpoplasty by laparoscopic modified Davydov's procedure. <i>Gynecologic Oncology</i> , 2017, 144, 647-648.	1.4	0
297	Physician-to-physician communication in breast cancer care coordination. <i>Bulletin Du Cancer</i> , 2017, 104, 690-693.	1.6	0
298	A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial. <i>Contemporary Clinical Trials</i> , 2018, 65, 151-156.	1.8	0
299	18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. <i>Diagnostics</i> , 2021, 11, 1353.	2.6	0
300	Facteurs de décision en chirurgie. , 2012, , 57-71.		0